| Literature DB >> 29039509 |
Kai Li1, Chuanwei Zhang1, Zichao Yang1, Yuliang Wang1, Haipeng Si2.
Abstract
Dry eye is a common eye disease, and suitable animal models are indispensable for investigating the pathogenesis and developing treatments for dry eye. The present study was conducted to develop an androgen deficiency dry eye model induced by finasteride, and to evaluate ocular surface status and inflammatory cytokine gene expression in the lacrimal gland using a cytokine antibody array system. The results revealed that the antiandrogenic drug finasteride induced significant tear deficiency, and the histopathology results revealed significant inflammatory cell infiltration in the lacrimal gland. The cytokine antibody array system identified increased B7‑2 (also known as cluster of differentiation 86), interleukin (IL)‑1β, IL‑4, IL‑6, IL‑10, matrix metalloproteinase‑8, Fas ligand, tumor necrosis factor (TNF)‑α and metalloproteinase inhibitor 1 levels in the lacrimal gland of the dry eye model. These cytokines were validated as candidate markers through the use of western blot analysis and reverse transcription‑quantitative polymerase chain reaction. Both analyses confirmed a significant increase in proinflammatory cytokines, including IL‑1β, IL‑6 and TNF‑α, and anti‑inflammatory cytokines, including IL‑4 and IL‑10. The aforementioned data suggested that inflammation in antiandrogenic models resulted from a balance between inflammatory and anti‑inflammatory responses. Thus, direct finasteride administration may produce an applicable model for dry eye mediated by androgen deficiency. In addition, there may be a correlation between sex, steroid deficiency and the inflammatory response. The findings of the present study have provided useful information for the pathogenesis and diagnosis of dry eye mediated by androgen deficiency.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29039509 PMCID: PMC5779951 DOI: 10.3892/mmr.2017.7754
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Position of 35 rat inflammatory factors in the antibody-based protein microarray.
| A | B | C | D | E | F | G | H | I | J | K | L | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | POS | POS | NEG | NEG | Activin A | Agrin | B7-2/Cd86 | β-NGF | CINC-1 | CINC-2α | CINC-3 | CNTF |
| 2 | POS | POS | NEG | NEG | Activin A | Agrin | B7-2/Cd86 | β-NGF | CINC-1 | CINC-2α | CINC-3 | CNTF |
| 3 | Fas ligand | Fractalkine | GM-CSF | ICAM-1 | IFN-γ | IL-1α | IL-1β | IL-1 R6 | IL-2 | IL-4 | IL-6 | IL-10 |
| 4 | Fas ligand | Fractalkine | GM-CSF | ICAM-1 | IFN-γ | IL-1α | IL-1β | IL-1 R6 | IL-2 | IL-4 | IL-6 | IL-10 |
| 5 | IL-13 | Leptin | LIX | L-Selectin | MCP-1 | MIP-3α | MMP-8 | PDGF-AA | Prolactin R | RAGE | Thymus Chemokine-1 | TIMP-1 |
| 6 | IL-13 | Leptin | LIX | L-Selectin | MCP-1 | MIP-3α | MMP-8 | PDGF-AA | Prolactin R | RAGE | Thymus Chemokine-1 | TIMP-1 |
| 7 | TNF-α | VEGF | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | POS |
| 8 | TNF-α | VEGF | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | BLANK | POS |
POS, positive; NEG, negative; β-NGF, β nerve growth factor; CINC, cytokine-induced neutrophil chemoattractant; CNTF, ciliary neurotrophic factor; GM-CSF, granulocyte-macrophage colony stimulating factor; ICAM-1, intercellular adhesion molecule-1; IFN-γ, interferon-γ; IL, interleukin; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; RAGE, receptor for advanced glycation end products; TIMP, tissue-specific inhibitor of metalloproteinase; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
Primer sequence for the PCR in this experiment.
| Gene name | Sequence | Length (bp) |
|---|---|---|
| MMP8 | F: CGTGGCTGCTCATGAATTTG | 102 |
| R: TAGGTGCTGGGTTCTCTGTA | ||
| CNTF | F: TTGGAGATGGTGGTCTCTTTG | 100 |
| R: ATGACACGAAGGTCATGGATAG | ||
| FasL | F: GGTGCTAATGGAGGAGAAGAAG | 106 |
| R: TAAATGGTCAGCAACGGTAAGA | ||
| IL-1β | F: TCCCTGAACTCAACTGTGAAATA | 103 |
| R: GGCTTGGAAGCAATCCTTAATC | ||
| IL-4 | F: GTCACCCTGTTCTGCTTTCT | 96 |
| R: GACCTGGTTCAAAGTGTTGATG | ||
| IL-6 | F: GAAGTTAGAGTCACAGAAGGAGTG | 105 |
| R: GTTTGCCGAGTAGACCTCATAG | ||
| IL-10 | F: AGTGGAGCAGGTGAAGAATG | 109 |
| R: GAGTGTCACGTAGGCTTCTATG | ||
| GAPDH | F: GGGAAACCCATCACCATCTT | 72 |
| R: ATACTCAGCACCAGCATCAC |
MMP, matrix metalloproteinase; CNTF, ciliary neurotrophic factor; FasL, Fas ligand; IL, interleukin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 1.Effect of finasteride administration on tear production. (A) Tear secretion changes in the three groups at different time points (unit: mm); (B) BUT changes in the three groups at different time points (unit: sec); (C) changes in corneal epithelial fluorescein staining in the three groups at different time points *P<0.05/**P<0.01 vs. baseline within the same group. ▲P<0.05/▲▲P<0.01 within the Con group at the same time point. BUT, break up time.
Cytokine assay results in lacrimal gland of three groups.
| Name of cytokines | Folds of group Sal to Con lacrimal gland | Folds of group Fin to Con lacrimal gland |
|---|---|---|
| Inflammatory cytokines | ||
| IL-1α | 1.191 | 1.220 |
| IL-1β | 0.990 | 1.533↑ |
| IL-2 | 1.004 | 1.283 |
| IL-6 | 0.951 | 1.357↑ |
| IFN-γ | 1.125 | 1.827↑ |
| Fas ligand | 0.772 | 3.096↑ |
| GM-CSF | 0.867 | 1.952↑ |
| TNF-α | 0.721 | 1.541↑ |
| Anti-inflammatory cytokines | ||
| IL-1 R6 | 0.949 | 1.334↑ |
| IL-4 | 0.857 | 1.716↑ |
| IL-10 | 0.816 | 1.593↑ |
| IL-13 | 0.904 | 1.435↑ |
| Chemokines | ||
| MCP-1 | 0.926 | 1.469↑ |
| MIP-3α | 1.306↑ | 1.375↑ |
| Fractalkine | 1.198 | 1.194 |
| CINC-1 | 1.114 | 1.136 |
| CINC-2α | 1.253 | 1.216 |
| CINC-3 | 1.216 | 1.229 |
| Thymus chemokine-1 | 1.125 | 1.085 |
| Growth factors | ||
| β-NGF | 1.441↑ | 1.448↑ |
| PDGF-AA | 1.323↑ | 1.330↑ |
| VEGF | 1.286 | 1.291 |
| CNTF | 0.872 | 1.809↑ |
| Activin A | 1.261 | 1.343↑ |
| Other cytokines | ||
| B7-2/Cd86 | 0.940 | 1.992↑ |
| Agrin | 1.034 | 1.054 |
| Leptin | 0.848 | 2.315↑ |
| MMP-8 | 0.640 | 3.304↑ |
| TIMP-1 | 1.045 | 1.528↑ |
| LIX | 1.246 | 1.295 |
| L-Selectin | 0.926 | 1.664↑ |
| Prolactin R | 1.240 | 1.232 |
| RAGE | 1.111 | 1.116 |
| ICAM-1 | 0.982 | 1.862↑ |
IL, interleukin; IFN-γ, interferon-γ; GM-CSF, granulocyte-macrophage colony stimulating factor; TNF, tumor necrosis factor; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; CINC, cytokine-induced neutrophil chemoattractant; β-NGF, β nerve growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; CNTF, ciliary neurotrophic factor; MMP, matrix metalloproteinase; TIMP, tissue-specific inhibitor of metalloproteinase; RAGE, receptor for advanced glycation end products; ICAM-1, intercellular adhesion molecule-1.
Figure 2.Microarray analysis of secreted inflammatory factors from lacrimal glands. (A) Lacrimal gland of the Con group; (B) lacrimal gland of the Sal group; (C) lacrimal gland of the Fin group.
Figure 3.Western blot analysis of cytokines in the lacrimal gland of the three groups of rats. *P<0.05, **P<0.01. MMP, matrix metalloproteinase; TIMP, tissue-specific inhibitor of metalloproteinase; IL, interleukin; FasL, Fas ligand; TNF, tumor necrosis factor.
Figure 4.Western blot analysis of secreted inflammatory factors from the lacrimal gland. (A) Con group; (B) Fin group. TIMP, tissue-specific inhibitor of metalloproteinase; IL, interleukin; TNF, tumor necrosis factor; MMP, matrix metalloproteinase; FasL, Fas ligand; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 5.Real-time PCR analysis of cytokines in lacrimal glands from the three groups of rats. *P<0.05, **P<0.01. MMP, matrix metalloproteinase; IL, interleukin; FasL, Fas ligand; TNF, tumor necrosis factor.
Figure 6.Lacrimal gland histopathology (H&E staining, ×400). (A) Lacrimal gland from the Con group; (B) Lacrimal gland from the Fin group. A large number of lymphocytes had infiltrated the interlobular space and surrounded the acinar and ductal cells as indicated by the black arrow. H&E, hematoxylin and eosin.